Biomerica 10-K/A Reveals CEO's $500K Related-Party Note and New Finance Chief
BMRA sits 65% above its 52-week low of $1.45 on light trading volume (0.1× avg).
Summary
Biomerica's 10-K/A discloses a $500,000 related-party sale of its Diagnosis S.A. stake to CEO Zackary Irani, the appointment of a new Principal Financial Officer, and detailed insider ownership showing B. Riley at 10%.
Key Events · Corporate Governance and Compliance · BMRA
-
CEO-Related $500K Diagnosis S.A. Sale
Company sold its entire 78,750-share stake in Diagnosis S.A. to CEO Zackary Irani and other purchasers for $500,000. CEO Irani holds a secured promissory note bearing 8% interest, maturing May 29, 2027, with principal outstanding as of September 28, 2026.
-
New Principal Financial Officer Appointed
Xiaoxuan (Jenny) Qu, age 33, was appointed Principal Financial Officer and Principal Accounting Officer effective August 27, 2026. Her employment agreement provides a $160,000 base salary and 12 months' severance upon termination without cause or for good reason.
-
B. Riley Holds 10% Ownership
B. Riley Principal Capital, LLC beneficially owns 460,080 shares, representing 10.0% of outstanding common stock as of September 28, 2026. CEO Zackary Irani owns 5.9% (275,679 shares).
-
Executive RSU Grants Disclosed
CEO Irani received 52,500 RSUs valued at $135,450 and EVP Barbieri received 30,000 RSUs valued at $77,400, both granted December 12, 2025 at $2.58 per share. Barbieri's RSUs cliff vest December 12, 2026.
Analysis · BMRA · Life Sciences
This amendment to Biomerica's annual report discloses several material governance items for the first time. Most notably, the company sold its entire minority stake in Diagnosis S.A. to CEO Zackary Irani and other purchasers for $500,000, with the CEO holding a secured promissory note bearing 8% interest that matures in May 2027. The filing also confirms the appointment of Xiaoxuan Qu as Principal Financial Officer effective August 27, 2026, and details her $160,000 base salary and severance terms. Against the backdrop of the company's going-concern warning and only $1.3M in cash disclosed in the original 10-K, the related-party transaction and new finance leadership are significant governance signals for a micro-cap company facing Nasdaq delisting risk.
How filings like this one have moved
In the 30 days to Oct 15, 2026, 28.9% of the 1476 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BMRA was trading at $2.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11M. The 52-week trading range was $1.45 to $3.21. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.